Hard-to-heal wounds are one of the major complications associated with diabetes, leading to limb amputation, disability and even death. There is an urgent need for novel therapeutics that are both effective and inexpensive for patients with diabetes who have hard-to-heal wounds.
K21 is a quaternary ammonium silane molecule that exhibits bactericidal, viricidal and fungicidal activity, with less toxicity and greater efficacy compared with other antiseptics such as chlorhexidine and benzalkonium chloride or antimicrobial silver. Biofilm colonization is also inhibited.
As an advanced wound care product, a novel nontoxic antiseptic with immunomodulatory activity would be hugely beneficial for such patients. K21 is one such novel antiseptic.
Company Details
- Employees
- 1
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://fitebacwoundcare.com
Fitebac Woundcare Questions
Fitebac Woundcare's website is https://fitebacwoundcare.com
Fitebac Woundcare's LinkedIn profile is https://www.linkedin.com/company/fitebacwoundcare
Fitebac Woundcare has
1 employees.
View email and phone details for 1
employees at Fitebac Woundcare.
Fitebac Woundcare's industry is
Biotechnology Research
Fitebac Woundcare's top competitors are
Siltech Corporation,
Fitebac Pharma,
Leaside Business Park Association,
Innovators Alliance,
Insideout Health + Wellness,
Baar Technologies,
Gbie,
Fitebac Technologies,
Mystique Brand Communications.
Fitebac Woundcare's categories are Biotechnology Research
Fitebac Woundcare's founding year is 2016
